Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Gilead Sciences

Related GILD
Analysts On Gilead: We Think They're Mobilizing For A Deal
Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price
Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ... (GuruFocus)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Gilead Sciences (NASDAQ: GILD), and raised its price target from $55.00 to $59.00.

Jefferies noted, “On its earnings call, GILD highlighted key interim Phase 3 data on 7977+5885 in 1Q13 (although GILD may not disclose it), as well as 12-week treatment data for 7977+ daclatasvir and ELECTRON data for 7977+5885 in GT1 naives (at AASLD in Nov), to determine the ideal 7977 regimen for GT1 HCV. We are positive on 7977 prospects and continue work on sizing the HCV market to better analyze valuation.”

Gilead Sciences closed on Tuesday at $64.91.

Latest Ratings for GILD

Mar 2017UBSDowngradesBuyNeutral
Feb 2017CitigroupDowngradesBuyNeutral
Nov 2016Stifel NicolausInitiates Coverage OnBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!